

An Efficient Approach for the Synthesis of Threo- α -Amino Epoxides

*Thesis submitted in partial fulfillment of the requirements
for the award of the degree of*

Masters of Science
In
Chemistry

Submitted by

Bandhana Sharma

Roll No: -301102002

Under the guidance of

Dr. Satyendra Kumar Pandey

to the




**School of Chemistry and Biochemistry
Thapar University
Patiala-147004 (Punjab)
INDIA
July 2013**

Candidate's Declaration


I hereby declare that the work being presented in the dissertation entitled "**An Efficient Approach for the Synthesis of Threo- α -Amino Epoxides**" in partial fulfillment of the requirements for the award of the degree of Masters in Chemistry, School of Chemistry and Biochemistry, Thapar University, Patiala, is my own work during the period of January to July 2013, under the supervision of **Dr. Satyendra Kumar Pandey**. My thesis has not previously formed the basis for award of any degree, diploma, or other similar title or recognition.

Patiala

Date: 15th July 2013


Bandhana Sharma

This is to certify that the above statement made by the candidate is correct and true to the best of our knowledge.


 15.07.2013

Dr. Satyendra Kumar Pandey

Project Supervisor,

Assistant Professor (SCBC),

Thapar University.



Dr. Satnam Singh

Head, SCBC


Thapar University.

Certificate


This is to certify that the project entitled "**An Efficient Approach for the Synthesis of Threo- α -Amino Epoxides.**" being submitted by **Ms. Bandhana Sharma** in the partial fulfillment of the requirement for the award of the degree of Masters of Science in the School of Chemistry and Biochemistry, Thapar University, Patiala, is a bonified work carried under the supervision of **Dr. Satyendra Kumar Pandey** and no part of this project has been submitted for award of any other degree by me.

 15-07-2013

Dr. Satyendra Kumar Pandey,
Assistant Professor,
Thapar University.


Head of the department,
(Dr. Satnam Singh)

School of Chemistry and Biochemistry,
Thapar University.


Dean of Academic Affairs,
(Dr. S.K. Mohapatra)
Thapar University.

ACKNOWLEDGEMENT

To make a project successful, there are many helping hands. I would like to express my heartiest appreciation to all those who support me and encourage me to complete my project.


I wish to express my profound gratitude and deep regards to my guide Dr. Satyendra Kumar Pandey for his exemplary guidance, monitoring and constant encouragement throughout the course of this Project work. The blessing, help and guidance given by him time to time shall carry me a long way in the journey of life on which I am about to embark.

I also take this opportunity to express a deep sense of gratitude to Dr. Satnam Singh for approving me for this project.

I am obliged to Mr. Yuvraj for his cordial support. I am grateful to all laboratory staff for their cooperation during the period of my assignment, which helped me in completing this task through various stages. In my daily work I have been blessed with a friendly and cheerful group of research scholars Ms. Sarita, Mr. Akul Sen Gupta and Ms. Richa Sharma. I would also like to thank Ms. Mandeep Kaur, Ms. Rupinder Kaur, Mr. Bupinder Singh, Ms. Meenakshi, Ms. Richa Goyal, Mr. Akul Sen Gupta, Research scholars for helping me with the lab apparatus.

I would like to express my heartiest thanks to my dear friends (Gaurav Sharma, Navneet Rathour, Poonam Sharma, Jyoti Sharma, Arpandeep Kaur, Parminder Kaur and Harsimran Sohi) for their Support and wishes for the successful completion of this project.

Lastly, I thank almighty, my beloved parents, brother (Abhinav sharma) and sister (Vanita sharma) for their constant encouragement and blessings without which this project would not be possible.


Bandhana Sharma

LIST OF CONTENT

CONTENTS	PAGE NO
1. INTRODUCTION	6-7
2. REVIEW OF LITERATURE	7-13
3. PRESENT WORK	
Objectives	13
4. RESULTS AND DISCUSSIONS	14-15
5. CONCLUSIONS	15
6. EXPERIMENTAL SECTION	
4.1 Synthesis of 2-(<i>R</i>)- <i>N</i> -phthalimido-3-buten-1-ol	15-17
4.2 Synthesis of (<i>S</i>)-2-(2-hydroxy-1-(oxiran-2-yl)ethyl) isoindoline -1,3-dione	
7. SPECTRA	17-29
REFERENCES	30-31

1. Introduction

Non-racemic α -amino epoxides are versatile synthetic modules since they undergo regio- and stereoselective attack by various nucleophiles. Nucleophilic ring opening of such epoxides provides a powerful synthetic core unit for the chiral 1,2-amino alcohols and has found widespread application in the synthesis of natural products¹, non-peptidic protease inhibitors^{2,3,4}, synthesis of hydroxyethylamine, hydroxyethylene dipeptide isosters, anti cancer and antibiotic products⁵⁻⁸, novel amino acids⁹⁻¹⁰, NMDA antagonists¹¹, potent inhibitors of aspartic acid proteases such as rennin¹² or HIV-protease¹³ and are also selective cysteine protease inactivators, while exhibiting no inhibitory activity towards serine proteases¹⁴⁻¹⁶. In view of such varied utilities, considerable effort has been directed in recent years towards stereoselective synthesis of non-racemic *threo*- and *erythro*- α -aminoepoxides.¹⁷

The first synthesis of an α -aminoepoxide (derived from an α -amino acid) was non-stereoselective, yielding a racemic mixture of the product. There are several methods currently available by which *erythro*- α -aminoepoxides can be prepared with high diastereoselectivities (90% de)¹⁸. They include reduction of N-protected- α -aminohalomethyl ketones^{19,20} or peptidyl bromomethanes,²¹ condensation of dihalomethane with N,N-dibenzyl- α -amino aldehydes,²² cyclization of 3-amino-1,2-diols,²³ epoxidation of N,N-doubly protected α -amino aldehydes, by sulfonium ylides,²⁴ and reductive amination of α -ketoepoxides²⁵ yield preferentially the corresponding *erythro*- α -amino- or peptidylepoxides. These synthetic routes were applied almost exclusively to hydrophobic α -aminoepoxides, bearing only simple alkyl or aryl side chains, either because they satisfied some specific requirements or in order to avoid synthetic complications. However, in contrast, the stereoselective synthesis of *threo*- α -aminoepoxides is poorly documented and confined to less than a handful of methods that are either lengthy and/or plagued with methodological problems, thus representing a major synthetic hurdle in contemporary asymmetric synthesis. At present, *threo*- α -amino epoxides are best prepared via (i) diastereoselective epoxidation of enantiopure secondary allyl amines (prepared by Wittig reaction of enantiopure α -aminoaldehydes, either the phosphorus ylides of acetone, ethyl acetate, acetonitrile, etc., or phosphonates),^{26,27} (ii) reactions of enantiopure *N*-Boc α -amino aldehydes with sulfonium/arsonium ylides,^{28,29} and (iii) LAH reduction of chiral pool derived *N,N*-dibenzyl α -amino chloromethylketones followed by MeLi induced epoxide formation.³⁰ While the former two suffer from methodological problems arising from handling the sensitive

chemicals and racemization-prone α -aminoaldehydes, the latter method which, although avoids the use of α -aminoaldehydes, nevertheless requires a non-conventional procedure for the preparation of the starting chloromethylketones.

In view of these problems, and given the enormous potential of *threo*- α -aminoepoxides in the synthesis of *syn*-1,2- amino alcohols which are common structural units present in a number of anti-HIV dipeptide isosteres and new generation pharmaceuticals, it is highly desirable that new and improved procedures be developed for their stereoselective synthesis. To this end, we now describe a facile new synthetic protocol which, while using conventional and chemically stable intermediates, delivers *threo*- α -amino, β -hydroxyepoxides **1a** in a short synthetic pathway and with high diastereoselectivity than erythro- α -amino, β -hydroxyepoxide **1b** (Figure 1).





Figure 1.

1. Review of literature

Luly *et al.* (1987)²⁶

Luly and co-worker reported an efficient approach for the synthesis, key steps include the synthesis of amino aldehyde **3** by reduction (DIBAL-H) of ester **2** or by oxidation of N-protected amino alcohol.




Scheme 1.

The olefination of aldehyde **3** with unstabilized ylides gave the protected allylic amine **4** in good to excellent optical purity. As desired, epoxidation of olefin **4** with 3-chloroperoxybenzoic acid afforded mainly the threo stereochemistry **5a**.

Albeck et al. (1994)²⁸

Amnon Albeck' and co-worker reported a synthetic route for the preparation of *threo* peptidyl epoxides (Scheme 2). Tritylation of α -amino esters **1** was followed by DIBAL-H reduction. *N*-trityl- α -amino aldehydes **4** were obtained either directly or, in the case of full reduction, after a subsequent Swern oxidation of the corresponding alcohols **3**. Both steps proceeded in




Scheme 2. Reagents and conditions: (i) Ph_3CCl , Et_3N , CH_2Cl_2 ; (ii) DIBAL-H, toluene; (iii) LAH, Et_2O ; (iv) DMSO, $(\text{COCl})_2$; (v) $\text{Ph}_3\text{P}=\text{CH}_2$, THF (vi) HCl , acetone; (vii) Cbz-aa₃aa₂, DCC, NHS; (viii) *m*-CPBA, CH_2Cl_2 .

very high yield. Wittig reaction of the *N*-trityl- α -amino aldehydes **4** with methyldiene triphenylphosphorane afforded the corresponding olefins **5** in high yield. Deprotection under acidic conditions yielded allylamines **6**. Re-protection (from *N*-Boc or *N*-Cbz allylamines) and epoxidation furnished the known *threo* *N*-protected α -amino epoxides.

Albeck et al. (1997)¹⁸


Amnon Albeck and co-worker reported an efficient approach for the synthesis of erythro *N*-protected α -amino epoxides, which is based on a key stereoselective reduction of α -amino haloketones. It utilizes the chirality of α -amino acids to induce a preferred configuration at the new adjacent chiral center. The fate of the reduction depends very much on the halide, chloroketones being reduced to the corresponding chlorohydrins and bromoketones being reduced and spontaneously cyclized to the corresponding epoxides under the reaction conditions. In this study, they used the α -amino acids bearing a protected functional group at their side chains were subjected to the same procedure, yielding the corresponding doubly protected α -amino epoxides. In addition, removal of the side chain protecting group either prior or subsequent to the epoxide formation was also carried out. This general approach is summarized in Scheme 3.



Scheme 3. Reagents and conditions: (i) $\text{ClCO}_2\text{CH}_2\text{CHMe}_2$; NMM, THF; (ii) CH_2N_2 , Et_2O ; (iii) HCl (g); (iv) NaBH_4 , EtOH; (v) NaOMe, MeOH; (vi) HBr (aq); (vii) selective deprotection: 1,4-cyclohexadiene, Pd/C, EtOH; or TFA, CH_2Cl_2 .

Jose M. Concellon *et al.* (1997)³⁰

Jose M. Concellon and co-worker reported the synthesis of erythro- α -aminoepoxide in which they treated a mixture of diiodomethane and different *N,N*-dibenzylated *R*-amino aldehydes **1** with samarium metal at 0°C gave, after hydrolysis, the corresponding iodohydrins **2** (Scheme 4). When iodohydrins were taken to dryness they became unstable and decomposed to a mixture of several products. In order to characterize compounds **2** they were transformed into their *O*-acetyl derivatives **3** by treatment with acetic anhydride at room temperature, and these could be isolated and purified by flash column chromatography. Reaction of iodohydrins **2** with NaH at room temperature led to *erythro* amino epoxides **4**. The stereochemistry of amino epoxides **4** was established unambiguously by comparison of their NMR spectra with those previously reported. The iodomethylation of amino aldehydes **1** with Sm/CH₂I₂ took place with good diastereoselectivity. The diastereomeric excess (de) of compounds **2a-c** was higher than 80%, as determined by 300-MHz ¹H NMR and quantitative ¹³C NMR spectroscopy.




Scheme 4. Reagents and conditions: (i) Sm⁰/CH₂I₂, THF, 0 °C, 40 min, then H₃O⁺; (ii) Ac₂O, pyridine, rt; (iii) NaH, CH₂Cl₂, rt; (iv) AgBF₄, Et₂O, rt; (v) H₂O.

Ernst Schaumann *et al.* (1998)¹

Ernst Schaumann and co-worker reported the synthesis of *threo* *N*-methyl oxirane **3** from (*S*)-*N*-methyl phenylalanine by bromoketone reduction or by epoxidation routes. The most extensively used pathways for the synthesis of amino epoxides are the epoxidation of the corresponding allyl amine for the *threo* isomer **3**. Epoxidation of olefin **6** gave the diastereomer **3** in only 39% yield along with considerable decomposition. Similar side


reactions leading to oxazolidinones and particularly decomposition had been observed by Rich on oxidation of an *N*-Boc- *N*-methyl derivate. To establish the relative configuration of the isolated oxirane, epoxide **3** was treated with sodium thiophenoxide leading to substituted *N*-methyl-oxazolidinone **7**.



Scheme 4. i) NMM/*i*-BuCO₂Cl/THF, CH₂N₂, 48% HBr, 72%, ii) NaBH₄/EtOH, -78⁰C→RT, 78%, iii) BH₃/THF, 0⁰C, 2h, 62%, iv) Py-SO₃/NEt₃/CH₂Cl₂/DMSO, 0⁰C→RT, 0.5h, 95%) Ph₃PCH₃⁺ Br⁻ /KHMDS, THF/DMSO, -78⁰C→ 40⁰C, 12h, 85%, vi) *m*-CPBA/CH₂Cl₂, 0⁰C→RT , 39% vii) PhSH/NaH/DMF, 2h , 88%.

Sengupta, S. et al. (1999)³¹

Saumitra Sengupta and co-worker reported the synthesis of *threo*- α -aminoepoxides started with the readily available *N*-phthaloyl (*N*-Pht) α -amino acids **1a–c**. The corresponding enantiopure α -amino diazoketones **2a–c** were prepared in good yields (60–70%) by



Scheme 5. Reagents and conditions: (i) SOCl₂, benzene, reflux, then CH₂N₂, ether, 0°C; (ii) 47% HBr, ether, 0°C; (iii) LiAlH(OBu-*t*)₃ (2 equiv.), THF, -20°C; (iv) NaH, THF, rt.

conventional procedures and were easily converted *via* HBr treatment (47% HBr, ether, 0°C) to the corresponding bromoketones **3a–c** in near quantitative yields (Scheme 5). The latter were subsequently reduced with LiAlH(OBu-*t*)₃ (2 equiv., THF, -20°C) to produce the respective bromohydrins **4a–c** (60–62%) with virtually complete *syn*-selectivity (*syn:anti*=95:5). LiAlH(OBu-*t*)₃, a bulky and highly chemoselective reducing agent, was found to be absolutely essential for this reduction since other reducing agents *viz.* NaBH₃(CN) or NaBH₄ caused extensive attack on the phthaloyl moiety. Small amounts of the *threo*-epoxides **5a–c** were also produced in this reduction step *via* in situ cyclization of the bromohydrins. Although the bromohydrins could be easily separated from the epoxides and cyclized to the latter, separately with NaH, they found it more convenient to treat this product mixture with NaH in THF at room temperature which smoothly produced the *threo*- α -amino epoxides **5a–c** in good overall yields (62–70%), starting from the respective bromoketones. The opposite result of the reduction of **3** leading to the *threo* and not to the expected *erythro* isomer may be explained by the Felkin-Anh (Figure 4) and the chelated Cram models (Figure 3) for addition reactions to α -chiral carbonyl compounds (Scheme 5). In the case of the unmethylated α - bromoketone the *erythro* selectivity is controlled by the formation of a chelate intermediate from the α -heterosubstituted carbonyl compound and the organometallic reagent.

Chelated Cram model³²




Figure 2.

Felkin Anh model^{33,34}

The high *syn*-selectivity observed in the bromoketone reductions can be rationalized by a Felkin non-chelation model such as **3**, in which the *N*-Pht moiety acts as a large electronegative group and the bulky reducing agent attacks this TS from the less hindered side. An alternative TS that would have led to the *anti*-bromohydrins is disfavored since it

would lead to severe non-bonding and dipolar repulsions between the *N*-Pht and the carbonyl groups. It is worthy of mention that such a high degree of *syn*-selectivity in the reduction of α -amino ketones has otherwise been observed only with the *N,N*-dibenzyl systems. The present observation that *N*-Pht α -amino ketones, having a more conventional amino protecting group than the *N,N*-Bn₂ system, can also be reduced with high *syn*selectivity, thereby promises a more attractive synthetic protocol for homochiral *syn*-1,2-amino alcohols, in general.




Figure 3.

2. Present Work

Objective:

Non-racemic α -amino epoxides are versatile synthetic modules since they provides a powerful synthetic core unit for homochiral 1,2-amino alcohols and in the synthesis of natural products. Various methods for the synthesis of *threo*- α -amino, β -hydroxyepoxide **1a** and *erythro*- α -amino, β -hydroxyepoxide **1b** have been documented in the literature. Most of these approaches employed chiral pool starting materials. As part of our research program aimed at developing enantioselective synthesis of α -amino epoxides, we became interested to develop a new and highly enantioselective synthesis of α -amino epoxides employing (*S,S*)-DACH-Phenyl Trost Ligand **2** (Figure 4) and *m*-CPBA as the source of diastereoselective epoxidation.





Figure 4. Structure of (*S,S*)-DACH-Phenyl Trost Ligand **2**.

3. Results and discussion

The synthesis of *threo*- α -amino epoxides **1a** started from commercially available phthalimide **4** as illustrated in Scheme 8. The compound phthalimide **4** was treated with butadiene monoepoxide **3** using (*S,S*)-DACH-Phenyl Trost Ligand **2** to afford 2-(*R*)-*N*-phthalimido-3-buten-1-ol **5** as a single isomer in 95% yield with 100% ee. With enantiomerically pure 2-(*R*)-*N*-phthalimido-3-buten-1-ol **5** in hand, we then subjected it to epoxidation with *m*-CPBA to afford the *threo*- α -amino epoxides **1a** and *erythro*- α -amino epoxides **1b** in excellent yield of 85% (80% de). The IR spectrum of 2-(*R*)-*N*-phthalimido-3-buten-1-ol **5** shows the



Scheme 8. Reagents and conditions: i) (*S,S*)-DACH-naphtyl, 0.4 mol % $[n^3-(C_3H_5)PdCl]_2$, Na_2CO_3 in DCM, rt, 14h; ii) *m*-CPBA, rt, 12h.

hydroxyl peak at 3460 cm^{-1} , carbonyl absorption at 1774 cm^{-1} and olefinic C=C stretching at 1708 cm^{-1} . The proton NMR spectrum of 2-(*R*)-*N*-phthalimido-3-buten-1-ol **5** indicates the aromatic peak at 7.74 (dd, two protons), 7.85 (dd, two protons) hydrogen at chiral carbon at 4.15 (ddd, one proton) and olefinic hydrogen at 6.12-6.19 (multiplet, one proton). The ^{13}C NMR spectrum of 2-(*R*)-*N*-phthalimido-3-buten-1-ol **5** shows carbonyl carbon at 168.7, olefinic carbon at 131.8 and chiral carbon appeared at δ 56. The DEPT-135 NMR of 2-(*R*)-*N*-phthalimido-3-buten-1-ol **5** gave two peaks showing two $-CH_2$ at δ 63.0 and 119.0. The IR spectrum of **1a** gave hydroxyl peak at 3467 cm^{-1} , carbonyl absorption at 1775 cm^{-1} and aromatic C=C stretching at 1713 cm^{-1} . The proton NMR spectrum of **1a** gave methoxy peak at 4.04-4.08 (multiplet, one proton), hydrogen at chiral carbon at 4.11-4.15 (multiplet, two proton) and 2.93 (triplet, one proton). The ^{13}C NMR of **1a** gave carbonyl carbon at 168.6 and chiral carbon appeared at δ 49.7 and δ 55.8. The IR spectrum of **1b** gave hydroxyl peak at 3465 cm^{-1} , carbonyl absorption at 1774 cm^{-1} and aromatic C=C stretching at 1712 cm^{-1} . The proton NMR spectrum of **1b** gave methoxy peak at 4.09 (dd, two proton), hydrogen at chiral carbon at 4.30 (quartet, two protons) and 2.80 (triplet, one proton). The ^{13}C


NMR of **1b** gave carbonyl carbon at 168.7 and chiral carbon appeared at δ 49.6 and δ 55.6. The DEPT-135 NMR of **1a** and **1b** gave two peaks showing two $-\text{CH}_2$ at delta 46.0 and 61.0.

4. Conclusion

In conclusion, a practical and distereoselective synthesis of *threo*- α -amino epoxides **1a** has been achieved employing (*S,S*)-DACH-Phenyl Trost Ligand and *m*-CPBA epoxidation. The synthesis strategy describe as significant potential for further extension to other isomers and related analogues including natural products, non-peptidic protease inhibitors, synthesis of hydroxyethylamine, hydroxyethylene dipeptide isosters, anti cancer and antibiotic products, novel amino acids, NMDA antagonists, potent inhibitors of aspartic acid proteases such as rennin or HIV-protease.

5. Experimental section

6.1 Synthesis of 2-(*R*)-*N*-phthalimido-3-bueten-1-ol **5**:



In a 250 mL flamed-dried flask, Na_2CO_3 (53 mg, 0.05 mmol), phthalimide (**4**) (1.47 g, 10 mmol), $[(\eta^3\text{-C}_3\text{H}_5)\text{PdCl}]_2$ (14.6 mg, 0.04 mmol) and *S,S* ligand **2** (94.6 mg, 0.12 mmol) were added under argon being the flask purged three times with argon. Then dry dichloromethane (80 mL) was added to the mixture and the solution was stirred 15 min at rt. Butadiene monoepoxide **3** (810 μl , 10 mmol) was added in one portion and the resulting mixture was stirred at rt for 14h. The resulting mixture was concentrated and purified by flash chromatography, using 1:1 hexanes:ethyl acetate as a solvent, to afford compound **5** (99%) as a white solid.

Yield: 2.08g, 96%

Mp: 276 °C.

IR: (neat, cm^{-1}): ν_{max} 3460, 1774, 1708, 1388.


^1H NMR (400 MHz, CDCl_3): δ 2.76 (dd, $J=3.68\text{Hz}$, 8.24Hz, 1H), 3.97 (ddd, $J=4.16\text{Hz}$, 12.44 Hz, 8.12Hz, 1H), 4.15 (ddd, $J=3.96\text{Hz}$, 7.6Hz, 12.22Hz, 1H), 4.94 (q, $J= 3.20\text{Hz}$,

7.76Hz, 1H), 5.29 (dd, $J=0.88\text{Hz}$, 9.6Hz , 2H), 6.12-6.19 (m, 1H), 7.74(dd, $J=3.2\text{Hz}$, 5.48Hz , 2H), 7.85 (dd, $J= 2.76\text{Hz}$, 5.52Hz , 2H)

^{13}C NMR (100 MHz, CDCl_3): δ 56.0, 62.9, 118.9, 123.5, 131.8, 132.0, 134.3, 168.7.

DEPT-135 ^{13}C NMR (100 MHz, CDCl_3): δ for $-\text{CH}_2$ carbon 56, 119.

6.2 Synthesis of 2-((S)-2-hydroxy-1-((S)-oxiran-2-yl)ethyl)isoindoline-1,3-dione.



General Procedure: To 250mg (1.5 mmol) of 2-(*R*)-*N*-phthalimido-3-buten-1-ol **5** in DCM (70ml) was added 380mg (0.2 mmol) and *m*-CPBA. The reaction mixture was then stirred at 0°C to room temperature over 12 hours. Then the reaction mixture was quenched with saturated NaHCO_3 solution and extracted with CHCl_3 (3 x 20ml) and concentrated under reduced pressure to get the crude product. Silica gel column chromatography (100-200 mesh) purification of the crude compound by using hexane/EtOAc (7:3) furnished epoxides **1a** and **1b** in diastereomeric ratio of 80% de.

6.2.1 2-((S)-2-hydroxy-1-((S)-oxirane-2-yl)ethyl)isoindoline-1,3-dione **1a**:

Yield: 182.56mg, 85%.

Mol. Formula: $\text{C}_{12}\text{H}_{10}\text{NO}_2$

M.P: 324°C

IR: (neat, cm^{-1}): ν_{max} 3467, 1775, 1713, 1387.

^1H NMR (400 MHz, CDCl_3): (LS): δ 2.77 (dd, $J=2.76\text{Hz}$, 5.6Hz , 1H), 2.93 (t, $J=4.6\text{Hz}$, 1H), 3.37 (s, 1H), 3.59-3.61 (m, 1H), 4.04-4.08 (m, 1H), 4.11-4.15 (m, 2H), 7.73 (dd, $J=3.2\text{Hz}$, 5.48 , 2H), 7.84 (dd, $J= 3.2\text{Hz}$, 5.48 , 2H).

^{13}C NMR (100 MHz, CDCl_3) : δ 46.4, 49.7, 55.8, 60.9, 123.4, 131.5, 134.2, 168.6

DEPT-135 ^{13}C NMR (100 MHz, CDCl_3): δ 46.0, 61.0.

6.2.2 2-((S)-2-hydroxy-1-((R)-oxirane-2-yl)ethyl)isoindoline-1,3-dione **1b**:

Yield: 45.64mg, 85%.

Mol. Formula: C₁₂H₁₀NO₂

M.P: 324 °C

IR: (neat, cm⁻¹): ν_{\max} 3465, 1774, 1712, 1387.

¹H NMR (400 MHz, CDCl₃): (US): δ 1.29 (s, 1H), 2.65-2.67 (m, 1H), 2.80 (t, J=3.68Hz, 1H), 3.55-3.56 (m, 1H), 4.07-4.09 (dd, J=5.04Hz, 10.52Hz, 2H), 4.30 (q, J=2.28Hz, 8.24Hz, 1H), 7.76 (dd, J=0.92Hz, 3.64Hz, 2H), 7.86 (dd, J=1.84Hz, 3.0Hz, 2H).

¹³C NMR (100 MHz, CDCl₃): δ 46.1, 49.6, 55.6, 61.4, 123.7, 131.7, 134.5, 168.7.

DEPT-135 ¹³C NMR (100 MHz, CDCl₃): δ 46.0, 61.0.

7. Spectra

1. IR, ¹H, ¹³CNMR and DEPT-135 ¹³CNMR spectra of **5**.
2. IR, ¹H, ¹³CNMR and DEPT-135 ¹³CNMR spectra of **1a**.
3. IR, ¹H, ¹³CNMR and DEPT-135 ¹³CNMR spectra of **1b**.



```

---- PROCESSING PARAMETERS ----
dg balance : 0 : PMST
temp auto : 2
weights : 0 [g] : 80 [g] : 100 [g]
irt : 1
method : PMST
deconvol : 1
Peak list : 0 [ppm] : 0.1 [ppm] : peaks : 0
ppm
  
```

```

File name      = SIR-1_CAMP04_3.d
Author         = ds1tx
Experiment     = siryle_pulse_dec
Sample ID     = SIR-1
Solvent       = CHLOROFORM-D
Acquisition time = 21-02-2015 22:13:31
Scan list type = 3-200-2015 22:13:31
Current type  = 3-200-2015 22:12:07
  
```

```

Comment       = SIRINOLIX
Data format   = ID CORELIX
Dm_s1_so     = 35214
Dm_t1_t10   = 13C
Dm_w1_w10   = [ppm]
Dm_s1_so     = X
  
```

```


Spectrum over = 0MS 400
                = 0MS-255400
  
```

```

Pulse strength = 9.3397561 [V] (6400 [pH])
X_2sol duration = 1.04833512 [s]
X_2sol         = 13C
X_2sol         = 52530333 [MHz]
X_order       = 100 [ppm]
X_points      = 32718
X_resolution  = 4
X_resolution  = 0.9584665 [MHz]
X_sweep       = 18
  
```

```

Irr_dobahn   = 399.7321938 [MHz]
Irr_freq     = 5 [ppm]
Clipped      = PMST
Mod_revern   = 1
Scale        = 14
Total_scaus  = 14
  
```





X: parts per Million: 13C



---- PROCESSING PARAMETERS ----
 de_balance : 0 : PULSI
 comp_ratio : 2 : 80 [%] : 100 [%]
 comp_ratio2 : 0 [%] : 80 [%] : 100 [%]
 file : 1
 MethodName :
 deconv : 1 [0] : 1
 deconv : 1 [0] : 1
 peak_list : 0 [ms] : 0.1 [ppm] : peaks : 0
 ppp :

File name = S13-1.DIR\T135-3_3.D
 Author = 06124
 Experiment = deconv2
 Sample ID = S13-1
 Solvent = CH2D2O(DMS-D)
 Creation_time = 21-APR-2013 22:14:46
 Revision_time = 21-APR-2013 18:58:25
 Current_time = 3-APR-2013 22:48:41
 Comment = SATTINDRA
 DataFormat = ID CORRELIX
 Dp_size = 26214
 Dp_title = 13C
 Dp_units = [ppm]
 Dimensions = X
 Site = DMS 400
 Spectrometer = QNP-DEC400
 Field strength = 9.382768174 (400) [MHz]
 K_AcqDuration = 1.043333121 [s]
 K_Gain = 130
 K_Treq = 100.52530333 [MHz]
 K_Offset = 100 [ppm]
 K_Pulses = 32788
 K_PowerMag = 4
 K_IsoNutation = 0.9546658114
 K_Sweep = 31.407035181 [MHz]
 IIR_Domain = 329.73219833 [MHz]
 IIR_Mag = 10
 IIR_Offset = 0 [ppm]
 Clipped = PULSI
 Hook_return = 1
 Scale = 14
 Total_scaus = 14
 K_AcqTime = 1.043333121 [s]
 K_Acq = 4.31 [dB]
 K_Pulse = 8.315 [us]
 IIR_Acq = 0.31 [dB]
 IIR_Acq_Dec = 21.734 [dB]
 IIR_Pulse = 9.715 [us]
 Decomp_Lin = TXW
 Dynical_salt = 11 [s]
 V_concave = 14.0 [Hz]
 Acqr_gain = 60
 Relaxation_delay = 21 [s]
 Selection_angle = 135 [deg]
 Selection_pulse = 14.63 [us]
 Temp_get = 18.7 [deg]






```

---- PROCESSING PARAMETERS ----
AQ Balance : 0.0000
Sample Name : 02
Sample Date : 06/01/2013
Sample ID : 0601
File Name : 0601
Acquisition : 0601
Acq. Date : 06/01/2013
Acq. Time : 22:43:57
PPM
Threshold : 5 [Hz] : 1
Peak List : 0 [Hz] : 0.1 [ppm] : 20 [Hz] : 01
Auto Reference : 5 [Hz]
  
```

```

File Name : SRR-2_Ls_1800MHz-4-3.d
INSTRUMENT : spect
PULPROG : zgpg30
AQ : 0.10000000
RG : 655.36
SFO : 180.1327598
CH2: 180.1327598
F2: 180.1327598
F1: 180.1327598
F2 - F1 : 0.0000000
SOLVENT : DMS-d6
PROCNO : 1
PROCNAME : SRR-2_Ls
DATA FORMAT : ID CORELIX
DS - Size : 13.107
DS - Title : [ppm]
DS - Units : [ppm]
DS - Symbols : X
Site : DMS 400
Spectrometer : OMN-DSS400
P1: 0.00000000
P2: 0.00000000
P3: 0.00000000
P4: 0.00000000
P5: 0.00000000
P6: 0.00000000
P7: 0.00000000
P8: 0.00000000
P9: 0.00000000
P10: 0.00000000
P11: 0.00000000
P12: 0.00000000
P13: 0.00000000
P14: 0.00000000
P15: 0.00000000
P16: 0.00000000
P17: 0.00000000
P18: 0.00000000
P19: 0.00000000
P20: 0.00000000
P21: 0.00000000
P22: 0.00000000
P23: 0.00000000
P24: 0.00000000
P25: 0.00000000
P26: 0.00000000
P27: 0.00000000
P28: 0.00000000
P29: 0.00000000
P30: 0.00000000
P31: 0.00000000
P32: 0.00000000
P33: 0.00000000
P34: 0.00000000
P35: 0.00000000
P36: 0.00000000
P37: 0.00000000
P38: 0.00000000
P39: 0.00000000
P40: 0.00000000
P41: 0.00000000
P42: 0.00000000
P43: 0.00000000
P44: 0.00000000
P45: 0.00000000
P46: 0.00000000
P47: 0.00000000
P48: 0.00000000
P49: 0.00000000
P50: 0.00000000
P51: 0.00000000
P52: 0.00000000
P53: 0.00000000
P54: 0.00000000
P55: 0.00000000
P56: 0.00000000
P57: 0.00000000
P58: 0.00000000
P59: 0.00000000
P60: 0.00000000
P61: 0.00000000
P62: 0.00000000
P63: 0.00000000
P64: 0.00000000
P65: 0.00000000
P66: 0.00000000
P67: 0.00000000
P68: 0.00000000
P69: 0.00000000
P70: 0.00000000
P71: 0.00000000
P72: 0.00000000
P73: 0.00000000
P74: 0.00000000
P75: 0.00000000
P76: 0.00000000
P77: 0.00000000
P78: 0.00000000
P79: 0.00000000
P80: 0.00000000
P81: 0.00000000
P82: 0.00000000
P83: 0.00000000
P84: 0.00000000
P85: 0.00000000
P86: 0.00000000
P87: 0.00000000
P88: 0.00000000
P89: 0.00000000
P90: 0.00000000
P91: 0.00000000
P92: 0.00000000
P93: 0.00000000
P94: 0.00000000
P95: 0.00000000
P96: 0.00000000
P97: 0.00000000
P98: 0.00000000
P99: 0.00000000
P100: 0.00000000
  
```




X: parts per Million: 1H



```

---- PROCESSING PARAMETERS ----
ds_filename : 0 : PALS1
exp_name : 2 :
exp_date : 0 [R] : 00 [R] : 100 [R]
file_name : 1 :
path_prefix : 0 [R] :
acq_method : 2 :
dc_correct :
2 : scaling/base
dc_correct :
PALS
kappa : 5 [R] : 1
peak_pos : 0 [R] : 0.1 [ppm] : peaks : 0
auto_reference : 5 [R]
  
```



```

File name      = SKE-2-LS_CARBON-4-3.d
AUXYPR        = 0
Experiment     = single pulse_dec
Sample ID     = SKE-2-LS
Solvent       = CHLOROFORM-D
Creation time = 6-4PM-2013 22:44:50
Acquisition time = 6-7PM-2013 22:51:36
Current time  = 6-7PM-2013 22:52:13

Component     = PSONH4
Data format   = ID CORELTX
P1            = 12.2180
P2            = 12.2110
P3            = 12.2012
P4           = 12.1990
P5           = 12.1970
P6           = 12.1950
P7           = 12.1930
P8           = 12.1910
P9           = 12.1890
P10          = 12.1870
P11          = 12.1850
P12          = 12.1830
P13          = 12.1810
P14          = 12.1790
P15          = 12.1770
P16          = 12.1750
P17          = 12.1730
P18          = 12.1710
P19          = 12.1690
P20          = 12.1670
P21          = 12.1650
P22          = 12.1630
P23          = 12.1610
P24          = 12.1590
P25          = 12.1570
P26          = 12.1550
P27          = 12.1530
P28          = 12.1510
P29          = 12.1490
P30          = 12.1470
P31          = 12.1450
P32          = 12.1430
P33          = 12.1410
P34          = 12.1390
P35          = 12.1370
P36          = 12.1350
P37          = 12.1330
P38          = 12.1310
P39          = 12.1290
P40          = 12.1270
P41          = 12.1250
P42          = 12.1230
P43          = 12.1210
P44          = 12.1190
P45          = 12.1170
P46          = 12.1150
P47          = 12.1130
P48          = 12.1110
P49          = 12.1090
P50          = 12.1070
P51          = 12.1050
P52          = 12.1030
P53          = 12.1010
P54          = 12.0990
P55          = 12.0970
P56          = 12.0950
P57          = 12.0930
P58          = 12.0910
P59          = 12.0890
P60          = 12.0870
P61          = 12.0850
P62          = 12.0830
P63          = 12.0810
P64          = 12.0790
P65          = 12.0770
P66          = 12.0750
P67          = 12.0730
P68          = 12.0710
P69          = 12.0690
P70          = 12.0670
P71          = 12.0650
P72          = 12.0630
P73          = 12.0610
P74          = 12.0590
P75          = 12.0570
P76          = 12.0550
P77          = 12.0530
P78          = 12.0510
P79          = 12.0490
P80          = 12.0470
P81          = 12.0450
P82          = 12.0430
P83          = 12.0410
P84          = 12.0390
P85          = 12.0370
P86          = 12.0350
P87          = 12.0330
P88          = 12.0310
P89          = 12.0290
P90          = 12.0270
P91          = 12.0250
P92          = 12.0230
P93          = 12.0210
P94          = 12.0190
P95          = 12.0170
P96          = 12.0150
P97          = 12.0130
P98          = 12.0110
P99          = 12.0090
P100         = 12.0070
  
```



```


---- 1H NMR SPECTRUM ----
dg balance : 0 : mg
temp auto : 2 : °C
temp set : 300.0 : K
int : 1
Machine : spect
dg correct : 0
Chem : 13C : 1
Peak List : 0 [ppm] : Peaks : 0
  
```

```


File Name = 300-2-13C_001135-3.jd
Author = do1ta
Experiment = dept_w2
Sample ID = 300-2-13C
Solvent = CD2D6000000-D
Creation Time = 6-4-2013 23:58:03
Revision Time = 6-4-2013 20:42:44
Current Time = 3-JUL-2013 22:53:50

Comment = 100MHz
Data Format = ID COREDMX
DP1 - 21 sec = 26.214
DP2 - 4.1 sec = 18.0
DP3 - 30.0 sec = 1.00 [ppm]
DP4 - 20.0 sec = 1.00 [ppm]
Site = DMS-400
Spectrum View = 001-025400

Field Strength = 9.38076170 (400 MHz)
K1 - 90 deg = 1.0433312125
K1 - 180 deg = 100.52530333 [MHz]
K1 - Offset = 337.63
K1 - Procs = 4
K1 - Prescans = 0.9584665194
K1 - Resol Time = 31.40055181 [MHz]
K1 - Sweep = 1H
K1 - Decoupl = 399.78219388 [MHz]
K1 - 13C = 51 [ppm]
K1 - Offset = 14.0 [MHz]
K1 - P1 = 1
K1 - P2 = 1
K1 - P3 = 1
K1 - P4 = 1
K1 - P5 = 1
K1 - P6 = 1
K1 - P7 = 1
K1 - P8 = 1
K1 - P9 = 1
K1 - P10 = 1
K1 - P11 = 1
K1 - P12 = 1
K1 - P13 = 1
K1 - P14 = 1
K1 - P15 = 1
K1 - P16 = 1
K1 - P17 = 1
K1 - P18 = 1
K1 - P19 = 1
K1 - P20 = 1
K1 - P21 = 1
K1 - P22 = 1
K1 - P23 = 1
K1 - P24 = 1
K1 - P25 = 1
K1 - P26 = 1
K1 - P27 = 1
K1 - P28 = 1
K1 - P29 = 1
K1 - P30 = 1
K1 - P31 = 1
K1 - P32 = 1
K1 - P33 = 1
K1 - P34 = 1
K1 - P35 = 1
K1 - P36 = 1
K1 - P37 = 1
K1 - P38 = 1
K1 - P39 = 1
K1 - P40 = 1
K1 - P41 = 1
K1 - P42 = 1
K1 - P43 = 1
K1 - P44 = 1
K1 - P45 = 1
K1 - P46 = 1
K1 - P47 = 1
K1 - P48 = 1
K1 - P49 = 1
K1 - P50 = 1
K1 - P51 = 1
K1 - P52 = 1
K1 - P53 = 1
K1 - P54 = 1
K1 - P55 = 1
K1 - P56 = 1
K1 - P57 = 1
K1 - P58 = 1
K1 - P59 = 1
K1 - P60 = 1
K1 - P61 = 1
K1 - P62 = 1
K1 - P63 = 1
K1 - P64 = 1
K1 - P65 = 1
K1 - P66 = 1
K1 - P67 = 1
K1 - P68 = 1
K1 - P69 = 1
K1 - P70 = 1
K1 - P71 = 1
K1 - P72 = 1
K1 - P73 = 1
K1 - P74 = 1
K1 - P75 = 1
K1 - P76 = 1
K1 - P77 = 1
K1 - P78 = 1
K1 - P79 = 1
K1 - P80 = 1
K1 - P81 = 1
K1 - P82 = 1
K1 - P83 = 1
K1 - P84 = 1
K1 - P85 = 1
K1 - P86 = 1
K1 - P87 = 1
K1 - P88 = 1
K1 - P89 = 1
K1 - P90 = 1
K1 - P91 = 1
K1 - P92 = 1
K1 - P93 = 1
K1 - P94 = 1
K1 - P95 = 1
K1 - P96 = 1
K1 - P97 = 1
K1 - P98 = 1
K1 - P99 = 1
K1 - P100 = 1
  
```




X: ppm per Million: 13C






----- PROCESSING PARAMETERS -----
 dc balance : 0 : PASST
 samp_ave : 0.2
 timescans : 0 [s] : 60 [s] : 100 [s]
 ref : 1
 auto_integrate
 deconvolve
 fit : 1
 [Method: S [s]] : 1
 peak_list : 0 [Hz] : 0.1 [ppm] : 20 [Hz] : 0 []
 auto_reference : 5 [s]




File Name	= SRE-2 US PRODM-4 J dr
AcqDir	= 0917c
Experiment	= single_pulse_022
Sample ID	= SRE-2 US
Container	= CUM-2000-B
AcqDate_Time	= 04/01/2015 09:30:38
AcqTime	= 3 -JUL-2015 22:30:05
Current_Type	= 3 -JUL-2015 22:30:41
Comment	= SRE-2 US
Data Format	= ID COMBINE
DP_Side	= 13107
DP_Cycle	= 1H
DP_Units	= [ppm]
DP_Spectrum	= X
Site	= DCS 400
Spectrum	= 0M-DSC400
NUC1_strength	= 0.369165171 (4.00 [MHz])
NUC2_strength	= 2.18365954125
NUC3_strength	= 309.78219838 [MHz]
NUC4_strength	= 51 [ppm]
NUC5_strength	= 15334
NUC6_strength	= 1
NUC7_strength	= 0.457946851784
NUC8_strength	= 1H
NUC9_strength	= 399.78219838 [MHz]
NUC10_strength	= 51 [ppm]
NUC11_strength	= 1H
NUC12_strength	= 399.78219838 [MHz]
NUC13_strength	= 51 [ppm]
NUC14_strength	= PASST
NUC15_strength	= 1
NUC16_strength	= 200
NUC17_strength	= 200
NUC18_strength	= 0.75 [Hz]
NUC19_strength	= 2.18365954125
NUC20_strength	= 45 [ppm]
NUC21_strength	= 0.31 [ppm]
NUC22_strength	= 4.87 [Hz]
NUC23_strength	= ORX
NUC24_strength	= ORX
NUC25_strength	= PASST
NUC26_strength	= 34
NUC27_strength	= 412
NUC28_strength	= 6.18365954125
NUC29_strength	= 11 [ppm]
NUC30_strength	= 11 [ppm]



---- PROCESSING PARAMETERS ----
 acqname : 0 : FMS1
 expno : 1
 f1 : 100.625
 f2 : 100.625
 xz : 0
 xzphase : 0
 dq : 0
 chf : 5 [Hz] : 1
 peaklist : 0 [Hz] : 0.1 [ppm] : peaks : 0
 ppm



filename = SRR-2-MS_NMR135-3_04
 archive = de1ca
 experiment = dept_wt2
 sample_id = SRR-2-MS
 solvent = CDCl3
 creation_time = 2015-03-15 22:53:43
 acquisition_time = 2015-03-15 22:53:43
 current_type = 3-DIR-2D15 22:53:50
 =====
 Comment = PRODM
 DataFormat = ID CORELIX
 In_file = 35214
 In_title = 13C
 In_units = [ppm]
 In_dimensions = X
 Site = DCS 400
 Spectrometer = JNM-DX400
 =====
 P1 (s) = 9.3897681 [s] (4.00 [Hz])
 P2 (s) = 1.04333312 [s]
 P3 (s) = 13C
 P4 (s) = 100.52530333 [Hz]
 P5 (s) = 100 [ppm]
 P6 (s) = 32768
 P7 (s) = 4.95384651 [Hz]
 P8 (s) = 31.40705518 [Hz]
 P9 (s) = 139.73219333 [Hz]
 P10 (s) = 2799
 P11 (s) = 1
 P12 (s) = 1
 P13 (s) = 1
 P14 (s) = 15
 P15 (s) = 15
 P16 (s) = 15
 =====
 X : acq time = 1.04333312 [s]
 X : acq = 4.31 [dB]
 X : pulse = 8.37 [dB]
 X : acn = 0.31 [dB]
 X : acn_dec = 21.734 [dB]
 X : pulse = 9.715 [Hz]
 X : pulse = 27000
 X : initial_walt = 11 [s]
 X : coref = 140 [Hz]
 X : recvr_gain = 60
 X : selection_de13c = 21 [s]
 X : selection_wg13c = 135 [deg]
 X : selection_pulse = 14 [s] [Hz]
 X : temp_get = 18.3 [deg]



References

1. Beier, C.; Schaumann, E. *Synthesis* **1997**, 1296-1300.
2. Babine, R. E.; Bender, S. L. *Chem. Rev.* **1997**, 97, 1359.
3. March, D. R.; Fairlie D. P. In *Designing New Antiviral Drugs for AIDS: HIV-1 Protease and Its Inhibitors*; Wise, R., Ed.; R. G. Landes Publishers: Austin, TX, **1996**; p. 1.
4. Takahashi, K. *Aspartic Proteineases: Structure, Function, Biology and Biomedical Implications*; Plenum Press: New York, **1995**.
5. Ohfuné, Y.; Kurokawa, N. *Tetrahedron Lett.* **1984**, 25, 1587-1590.
6. Kurokawa, N.; Ohfuné, Y. *J. Am. Chem. Soc.* **1986**, 108, 6041-6043.
7. Shaw, K. J.; Luly, J. R.; Rapoport, H. *J. Org. Chem.* **1985**, 50, 4515-4523.
8. Jones, R. J.; Rapoport, H. *J. Org. Chem.* **1990**, 55, 1144-1146
9. Meffre, P.; Vo-Quang, L.; Vo-Quang, Y.; Le Goffic, F. *Tetrahedron Lett.* **1990**, 31, 2291-2294.
10. Tashiro, T.; Fushiya, S.; Nozoe, S. *Chem. Pharm. Bull.* **1988**, 36, 893-901.
11. Baker, R.; Leeson, P. D.; Williams, B. *J. Chem. Abstr.* **1992**, 116, 214339.
12. Greenlee, W. J. *Pharmaceutical Res.* **1987**, 28, 263.
13. Rich, D. H.; Sun, C.-H.; Vara Prasad, J. V. N.; Pathiasseril, A.; Toth, M. V.; Marshall, G. R.; Clare, M.; Mueller, R. A.; Houseman, K. *J. Med. Chem.* **1991**, 34, 1222.
14. Giordano, C.; Gallina, C.; Consalvi, V.; Scandurra, R. *Eur. J. Med. Chem.* **1990**, 25, 479-487.
15. Albeck, A.; Persky, R.; Kliper, S. *Bioorg. Med. Chem. Lett.* **1995**, 5, 1767-1772.
16. Albeck, A.; Fluss, S.; Persky, R. *J. Am. Chem. Soc.* **1996**, 118, 3591-3596.
17. Beier, C.; Schaumann, E.; Adiwijaja, G. *Synlett* **1998**, 41.
18. Albeck, A.; Estreicher, G. I. *Tetrahedron* **1997**, 53, 5325.
19. Albeck, A.; Persky, R. *Tetrahedron* **1994**, 50, 6333-6346.
20. Rotella, D. P. *Tetrahedron Lett.* **1995**, 36, 5453-5456.
21. Barluenga, J.; Baragafia, B.; Concellon, J. M. *J. Org. Chem.* **1995**, 60, 6696-6699.
22. Green, B. E.; Chen, X.; Norbeck, D. W.; Kempf, D. J. *Synlett* **1995**, 613-614.
23. Reetz, M. T.; Binder, J. *Tetrahedron Lett.* **1989**, 30, 5425-5428.
24. Pdgrier, L.; Petit, Y.; Larchev~que, M. *J. Chem. Soc., Chem. Commun.* **1994**, 633-634.
25. Romeo, S.; Rich, D. H. *Tetrahedron Lett.* **1994**, 35, 4939.
26. Luly, J. R.; Dellaria, J. F.; Plattner, J. J.; Soderquist, J. L.; Yi, N. *J. Org. Chem.* **1987**, 52, 1487.

27. Ashton, W. T.; Cantone, C. L.; Meurer, L. C.; Tolman, R. L.; Greenlee, W. J.; Patchett, A. A.; Lynch, R. J.; Schorn, T. W.; Strouse, J. F.; Siegel, P. K. S. *J. Med. Chem.* **1992**, *35*, 2103.
28. Albeck, A.; Persky, R. *J. Org. Chem.* **1994**, *59*, 653.
29. Barluenga, J.; Baragana, B.; Concellon, J. M. *J. Org. Chem.* **1995**, *60*, 6696.
30. Concellon, J. M.; Bernad, P. L.; Perez-Andres, J. A. *J. Org. Chem.* **1997**, *62*, 8902.
31. Sengupta S., Das D. *Tetrahedron: Asymmetry* **1999**, *28*, 1653-1659.
32. Mulzer, J. In *Houben-Weyl Methods of Organic Chemistry*, 4th ed., Vol. E21a; Helmchen, G., Hoffmann, R. W., Mulzer, J., Schaumann, E., Eds.; Thieme: Stuttgart **1995**; p 75.
33. Anh, N. T. *Top. Current. Chem.* **1980**, *88*, 145.
34. Caramella P.; Rondan, N. G.; Paddon-Row, M. N.; Houk, K. N. *J. Am. Chem. Soc.* **1981**, *103*, 2438.